Effects of Vaccination against COVID-19 in Chronic Spontaneous and Inducible Urticaria (CSU/CIU) Patients: A Monocentric Study.
COVID-19
SARS-CoV-2
chronic
cutaneous
reactions
skin
urticaria
vaccines
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
08
03
2022
revised:
22
03
2022
accepted:
23
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Patients affected by pre-existing chronic spontaneous/Inducible urticaria (CSU/CIU) still feel unsafe due to the potential risk of an Adverse Event Following Immunization (AEFI) and Cutaneous Adverse Reactions (CARs) of COVID-19 vaccines. The appropriate management in this field remains debated and evidence is still lacking. We considered 160 CSU/CIU patients in Omalizumab/antihistamine therapy who received two doses of Comirnaty/Moderna mRNA vaccines; 20 of them also received a booster dose. Urticaria Activity Score-7 (UAS7) was used to assess the severity of the disease. Demographics, medical history, AEFI and CARs outcome after vaccination were collected by administering a web-based questionnaire completed by phone interview. In total, 147 patients did not show urticaria relapse (91.88%). Worsening cutaneous symptoms were experienced by 13 of our patients (8.12%). Exacerbation had a mean duration of 2 days and 11 h and mostly occurred after the first dose (69.23%). Systemic mild side effects were experienced by 9 patients (5.62%). No severe reactions were observed. Omalizumab can potentially prevent CARs and AEFI; however, major problems were registered during the 2-month stop period scheduled in the treatment. We suggest patients should not undergo vaccination during this period. CSU/CIU exacerbations appear to be transient and can be managed by antihistamines.
Sections du résumé
BACKGROUND
BACKGROUND
Patients affected by pre-existing chronic spontaneous/Inducible urticaria (CSU/CIU) still feel unsafe due to the potential risk of an Adverse Event Following Immunization (AEFI) and Cutaneous Adverse Reactions (CARs) of COVID-19 vaccines. The appropriate management in this field remains debated and evidence is still lacking.
METHODS
METHODS
We considered 160 CSU/CIU patients in Omalizumab/antihistamine therapy who received two doses of Comirnaty/Moderna mRNA vaccines; 20 of them also received a booster dose. Urticaria Activity Score-7 (UAS7) was used to assess the severity of the disease. Demographics, medical history, AEFI and CARs outcome after vaccination were collected by administering a web-based questionnaire completed by phone interview.
RESULTS
RESULTS
In total, 147 patients did not show urticaria relapse (91.88%). Worsening cutaneous symptoms were experienced by 13 of our patients (8.12%). Exacerbation had a mean duration of 2 days and 11 h and mostly occurred after the first dose (69.23%). Systemic mild side effects were experienced by 9 patients (5.62%). No severe reactions were observed.
CONCLUSIONS
CONCLUSIONS
Omalizumab can potentially prevent CARs and AEFI; however, major problems were registered during the 2-month stop period scheduled in the treatment. We suggest patients should not undergo vaccination during this period. CSU/CIU exacerbations appear to be transient and can be managed by antihistamines.
Identifiants
pubmed: 35407429
pii: jcm11071822
doi: 10.3390/jcm11071822
pmc: PMC8999670
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Dermatol Ther. 2021 Nov;34(6):e15153
pubmed: 34622531
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
Dermatol Ther. 2020 Jan;33(1):e13204
pubmed: 31863562
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e172-e174
pubmed: 34751995
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
Allergy. 2022 Mar;77(3):734-766
pubmed: 34536239
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
J Control Release. 2021 May 10;333:511-520
pubmed: 33798667
Int J Dermatol. 2020 May;59(5):590-594
pubmed: 32048727
JAMA Dermatol. 2021 Aug 1;157(8):1000-1002
pubmed: 34160555
Allergy. 2021 Aug;76(8):2605-2607
pubmed: 33811344
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Cureus. 2021 Sep 19;13(9):e18102
pubmed: 34692313
JAAD Case Rep. 2022 Jan 21;:
pubmed: 35079616
Clin Transl Allergy. 2015 Aug 17;5:29
pubmed: 26284152
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):172-180
pubmed: 34661927
J Allergy Clin Immunol Pract. 2022 Mar;10(3):859-862
pubmed: 34979336
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2195-2208
pubmed: 33823316
Immunotherapy. 2020 Nov;12(16):1173-1181
pubmed: 32892673
Allergol Select. 2021 Apr 1;5:140-147
pubmed: 33842829
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
J Am Acad Dermatol. 2018 Sep;79(3):567-569
pubmed: 29438758